(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Canaan, Ebix, and Glatfelter.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Canaan (CAN) | 2.88 | 29.15% | 2023-12-20 12:16:04 |
| 2 | Ebix (EBIX) | 2.29 | 10.12% | 2023-12-20 12:11:58 |
| 3 | Glatfelter (GLT) | 1.78 | 9.2% | 2023-12-20 13:42:06 |
| 4 | Bionano Genomics (BNGO) | 1.74 | 7.41% | 2023-12-20 12:16:00 |
| 5 | Foot Locker (FL) | 31.42 | 6.4% | 2023-12-20 07:10:05 |
| 6 | Express (EXPR) | 8.43 | 6.31% | 2023-12-20 04:41:06 |
| 7 | Deluxe Corporation (DLX) | 20.31 | 5.02% | 2023-12-19 19:09:06 |
| 8 | FuelCell Energy (FCEL) | 1.53 | 4.8% | 2023-12-20 12:12:13 |
| 9 | Entergy Louisiana, LLC First Mortgage Bonds, 5.875% (ELA) | 5.09 | 4.73% | 2023-12-19 23:09:05 |
| 10 | Emergent Biosolutions (EBS) | 2.44 | 4.27% | 2023-12-19 21:10:07 |
The three biggest losers today are argenx SE, FedEx, and MicroVision.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | argenx SE (ARGX) | 336.37 | -25.68% | 2023-12-20 12:51:24 |
| 2 | FedEx (FDX) | 249.29 | -10.97% | 2023-12-20 12:55:06 |
| 3 | MicroVision (MVIS) | 2.58 | -7.19% | 2023-12-20 12:13:54 |
| 4 | Viking Therapeutics (VKTX) | 18.06 | -5.69% | 2023-12-20 12:17:58 |
| 5 | Aon plc (AON) | 295.66 | -5.54% | 2023-12-20 12:52:32 |
| 6 | Virgin Galactic (SPCE) | 2.50 | -5.3% | 2023-12-20 13:00:54 |
| 7 | Nio (NIO) | 8.36 | -5.21% | 2023-12-20 12:57:20 |
| 8 | Duke Energy Corporation 5.125% Junior Subordinated Debentures due 2073 (DUKH) | 25.28 | -4.82% | 2023-12-19 19:47:05 |
| 9 | DexCom (DXCM) | 117.40 | -4.78% | 2023-12-20 12:11:52 |
| 10 | Li Auto (LI) | 33.74 | -4.34% | 2023-12-20 12:16:42 |
Winners today
1. Canaan (CAN) – 29.15%
Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.
NASDAQ ended the session with Canaan jumping 29.15% to $2.88 on Thursday, after five consecutive sessions in a row of gains. NASDAQ slid 1.5% to $14,777.94, after five sequential sessions in a row of gains, on what was an all-around bearish trend exchanging session today.
Earnings Per Share
As for profitability, Canaan has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canaan’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth declined by 75.1%, now sitting on 160.89M for the twelve trailing months.
More news about Canaan.
2. Ebix (EBIX) – 10.12%
Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.
NASDAQ ended the session with Ebix jumping 10.12% to $2.29 on Thursday while NASDAQ slid 1.5% to $14,777.94.
Earnings Per Share
As for profitability, Ebix has a trailing twelve months EPS of $0.16.
PE Ratio
Ebix has a trailing twelve months price to earnings ratio of 14.28. Meaning, the purchaser of the share is investing $14.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.49%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ebix’s EBITDA is 0.96.
Volatility
Ebix’s last week, last month’s, and last quarter’s current intraday variation average was a positive 3.88%, a negative 0.05%, and a positive 6.66%.
Ebix’s highest amplitude of average volatility was 11.99% (last week), 6.66% (last month), and 6.66% (last quarter).
Sales Growth
Ebix’s sales growth is negative 53.8% for the ongoing quarter and negative 47.2% for the next.
Volume
Today’s last reported volume for Ebix is 2779490 which is 1.22% above its average volume of 2745870.
More news about Ebix.
3. Glatfelter (GLT) – 9.2%
Glatfelter Corporation, together with its subsidiaries, manufactures and sells engineered materials worldwide. It operates through three segments: Composite Fibers, Airlaid Materials, and Spunlace. The Composite Fibers segment offers food and beverage filtration materials for single-serve coffee and tea products; wallcover base materials for wallpaper manufacturers; metallized products that are used in labels, packaging liners, gift wraps, and other consumer product applications; composite laminates consisting of decorative laminates for use in furniture, household and commercial flooring, and other applications; and specialty engineered products, which are used in electrical energy storage, home, hygiene, and other engineered fiber-based applications. The Airlaid Materials segment supplies absorbent cellulose-based airlaid nonwoven materials that are used to manufacture consumer products, such as feminine hygiene and other hygiene products, specialty wipes, tabletop, adult incontinence, home care, and other consumer and industrial products. The Spunlace segment manufactures spunlace nonwovens for cleaning, high-performance materials, personal care, hygiene, and medical applications. The company was formerly known as P. H. Glatfelter Company. Glatfelter Corporation was founded in 1864 and is headquartered in Charlotte, North Carolina.
NYSE ended the session with Glatfelter jumping 9.2% to $1.78 on Thursday, following the last session’s upward trend. NYSE dropped 1.34% to $16,573.78, after two sequential sessions in a row of gains, on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Glatfelter has a trailing twelve months EPS of $-2.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.14%.
Volume
Today’s last reported volume for Glatfelter is 293997 which is 2.81% above its average volume of 285939.
Sales Growth
Glatfelter’s sales growth is 11.8% for the present quarter and 5% for the next.
Yearly Top and Bottom Value
Glatfelter’s stock is valued at $1.78 at 01:32 EST, way below its 52-week high of $4.87 and way higher than its 52-week low of $1.30.
More news about Glatfelter.
4. Bionano Genomics (BNGO) – 7.41%
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
NASDAQ ended the session with Bionano Genomics jumping 7.41% to $1.74 on Thursday, after two consecutive sessions in a row of gains. NASDAQ slid 1.5% to $14,777.94, after five successive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.
Earnings Per Share
As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.
Yearly Top and Bottom Value
Bionano Genomics’s stock is valued at $1.74 at 01:32 EST, way under its 52-week high of $22.90 and way above its 52-week low of $1.19.
More news about Bionano Genomics.
5. Foot Locker (FL) – 6.4%
Foot Locker, Inc., through its subsidiaries, operates as an athletic footwear and apparel retailer. The company engages in the retail of athletic footwear, apparel, accessories, equipment, and team licensed merchandise under the Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Eastbay, atmos, WSS, Footaction, and Sidestep brand names. As of January 29, 2022, it operated 2,858 retail stores in 28 countries across the United States, Canada, Europe, Australia, New Zealand, and Asia; and 142 franchised Foot Locker stores located in the Middle East and Asia. The company also offers its products through various e-commerce sites and mobile apps. Foot Locker, Inc. was founded in 1879 and is headquartered in New York, New York.
NYSE ended the session with Foot Locker jumping 6.4% to $31.42 on Thursday, following the last session’s upward trend. NYSE fell 1.34% to $16,573.78, after two sequential sessions in a row of gains, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Foot Locker has a trailing twelve months EPS of $0.87.
PE Ratio
Foot Locker has a trailing twelve months price to earnings ratio of 36.11. Meaning, the purchaser of the share is investing $36.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.51%.
Sales Growth
Foot Locker’s sales growth is negative 3.2% for the current quarter and negative 4.9% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Foot Locker’s EBITDA is 0.7.
Moving Average
Foot Locker’s worth is way higher than its 50-day moving average of $23.72 and way above its 200-day moving average of $27.98.
Yearly Top and Bottom Value
Foot Locker’s stock is valued at $31.42 at 01:32 EST, way below its 52-week high of $47.22 and way higher than its 52-week low of $14.84.
More news about Foot Locker.
6. Express (EXPR) – 6.31%
Express, Inc. provides apparel and accessories for women and men for various occasions under the Express brand. The company sells its products through its e-commerce website, express.com; and mobile app, as well as franchisees Express locations in Latin America. As of January 29, 2022, it operated 561 stores in 46 states across the United States, as well as in Puerto Rico. The company was formerly known as Express Parent LLC and changed its name to Express, Inc. in May 2010. Express, Inc. was founded in 1980 and is headquartered in Columbus, Ohio.
NYSE ended the session with Express rising 6.31% to $8.43 on Thursday, following the last session’s upward trend. NYSE fell 1.34% to $16,573.78, after two consecutive sessions in a row of gains, on what was an all-around down trend trading session today.
Earnings Per Share
As for profitability, Express has a trailing twelve months EPS of $55.17.
PE Ratio
Express has a trailing twelve months price to earnings ratio of 0.15. Meaning, the purchaser of the share is investing $0.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 309.58%.
Moving Average
Express’s worth is under its 50-day moving average of $8.87 and way below its 200-day moving average of $12.47.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Express’s EBITDA is 0.49.
Yearly Top and Bottom Value
Express’s stock is valued at $8.43 at 01:32 EST, way below its 52-week high of $29.40 and way above its 52-week low of $7.36.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.6%, now sitting on 1.79B for the twelve trailing months.
Previous days news about Express
- American express AXP is heading to a potential selling area. According to FXStreet on Wednesday, 20 December, "American Express Company (Amex), symbol AXP, is an American multinational financial services corporation that specializes in payment cards. "
More news about Express.
7. Deluxe Corporation (DLX) – 5.02%
Deluxe Corporation provides technology-enabled solutions to small businesses and financial institutions in the United States, Canada, Australia, South America, and Europe. It operates through four segments: Payments, Cloud Solutions, Promotional Solutions, and Checks. The company provides treasury management solutions, including remittance and lockbox processing, remote deposit capture, receivables management, payment processing, and paperless treasury management solutions, as well as payment exchange, and fraud and security services; web hosting and design services, data-driven marketing solutions and hosted solutions that comprise digital engagement, logo design, financial institution profitability reporting, and business incorporation services. It also offers business forms, accessories, advertising specialties, promotional apparel, retail packaging, and strategic sourcing services; and printed personal and business checks. The company was formerly known as Deluxe Check Printers, Incorporated and changed its name to Deluxe Corporation in 1988. Deluxe Corporation was founded in 1915 and is headquartered in Shoreview, Minnesota.
NYSE ended the session with Deluxe Corporation rising 5.02% to $20.31 on Thursday while NYSE dropped 1.34% to $16,573.78.
Earnings Per Share
As for profitability, Deluxe Corporation has a trailing twelve months EPS of $0.69.
PE Ratio
Deluxe Corporation has a trailing twelve months price to earnings ratio of 29.43. Meaning, the purchaser of the share is investing $29.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.03%.
Volatility
Deluxe Corporation’s last week, last month’s, and last quarter’s current intraday variation average was 1.04%, 0.40%, and 1.86%.
Deluxe Corporation’s highest amplitude of average volatility was 2.32% (last week), 1.65% (last month), and 1.86% (last quarter).
More news about Deluxe Corporation.
8. FuelCell Energy (FCEL) – 4.8%
FuelCell Energy, Inc., together with its subsidiaries, manufactures and sells stationary fuel cell energy platforms that decarbonize power and produce hydrogen. It offers SureSource 1500, a 1.4-megawatt (MW) platform; SureSource 3000, a 2.8 MW platform; SureSource 4000, a 3.7 MW platform; SureSource 250, a 250- kilowatt (kW) platform; SureSource 400, a 400-kW platform; and SureSource Hydrogen, a 2.3 MW platform that is designed to produce up to 1,200 kilograms of hydrogen per day for multi-megawatt utility, microgrid, and distributed hydrogen applications, as well as on-site heat and chilling applications. The company also provides SureSource platform in various configurations and applications, including on-site power, utility grid support, and microgrid, as well as distributed hydrogen; solutions for long duration hydrogen-based energy storage and electrolysis technology; and carbon capture, separation, and utilization systems. Its SureSource power plants generate electricity, heat, hydrogen, and water. In addition, the company provides turn-key solutions, including development, engineering, procurement, construction, interconnection, and operation services. It serves various markets, including utilities and independent power producers, industrial and process applications, education and health care, data centers and communication, wastewater treatment, government, microgrids, hydrogen transportation, food and beverage, and commercial and hospitality. The company primarily operates in the United States, South Korea, England, Germany, and Switzerland. FuelCell Energy, Inc. was founded in 1969 and is headquartered in Danbury, Connecticut.
NASDAQ ended the session with FuelCell Energy jumping 4.8% to $1.53 on Thursday while NASDAQ dropped 1.5% to $14,777.94.
Earnings Per Share
As for profitability, FuelCell Energy has a trailing twelve months EPS of $-0.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.79%.
Previous days news about FuelCell Energy
- Fuelcell energy (fcel) reports Q4 earnings: what key metrics have to say. According to Zacks on Tuesday, 19 December, "Here is how FuelCell Energy performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about FuelCell Energy.
9. Entergy Louisiana, LLC First Mortgage Bonds, 5.875% (ELA) – 4.73%
Envela Corporation, together with its subsidiaries, primarily buys and sells jewelry and bullion products to individual consumers, dealers, Fortune 500 companies, municipalities, school districts, and other organizations in the United States. It offers jewelry and fine-watch products, including bridal jewelry, fashion jewelry, custom-made jewelry, diamonds, and other gemstones, as well as watches and jewelry components. The company also buys and sells various forms of gold, silver, platinum, and palladium products, including United States and other government coins, private mint medallions, art bars, and trade unit bars; and numismatic items, such as rare coins, currency, medals, tokens, and other collectibles, as well as provides jewelry and watches repair services. In addition, it offers end-of-life electronics recycling services; disposal transportation and product tracking services; IT-asset disposition services, including compliance and data sanitization services; and services to companies in the areas of software upgrades, and hardware or networking capabilities, as well as moving to cloud services. As of December 31, 2021, Envela Corporation marketed its products and services through six retail locations under the Dallas Gold & Silver Exchange name; and one retail location under the Charleston Gold & Diamond Exchange name, as well as through cgdeinc.com, dgse.com, echoenvironmental.com, ITADUSA.com, availrecovery.com, and teladvance.com e-commerce sites. The company was formerly known as DGSE Companies, Inc. and changed its name to Envela Corporation in December 2019. Envela Corporation was incorporated in 1965 and is headquartered in Irving, Texas.
NYSE ended the session with Entergy Louisiana, LLC First Mortgage Bonds, 5.875% jumping 4.73% to $5.09 on Thursday, following the last session’s upward trend. NYSE slid 1.34% to $16,573.78, after two successive sessions in a row of gains, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months EPS of $0.44.
PE Ratio
Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months price to earnings ratio of 11.57. Meaning, the purchaser of the share is investing $11.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.47%.
More news about Entergy Louisiana, LLC First Mortgage Bonds, 5.875%.
10. Emergent Biosolutions (EBS) – 4.27%
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
NYSE ended the session with Emergent Biosolutions rising 4.27% to $2.44 on Thursday while NYSE fell 1.34% to $16,573.78.
Earnings Per Share
As for profitability, Emergent Biosolutions has a trailing twelve months EPS of $-15.56.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.63%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 1.11B for the twelve trailing months.
Yearly Top and Bottom Value
Emergent Biosolutions’s stock is valued at $2.44 at 01:32 EST, way under its 52-week high of $16.66 and way above its 52-week low of $1.81.
More news about Emergent Biosolutions.
Losers Today
1. argenx SE (ARGX) – -25.68%
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
NASDAQ ended the session with argenx SE sliding 25.68% to $336.37 on Thursday while NASDAQ slid 1.5% to $14,777.94.
Earnings Per Share
As for profitability, argenx SE has a trailing twelve months EPS of $-4.12.
Revenue Growth
Year-on-year quarterly revenue growth grew by 132%, now sitting on 1.03B for the twelve trailing months.
Volatility
argenx SE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.44%, a negative 0.43%, and a positive 1.39%.
argenx SE’s highest amplitude of average volatility was 0.92% (last week), 1.66% (last month), and 1.39% (last quarter).
Sales Growth
argenx SE’s sales growth is 96.2% for the present quarter and 66.6% for the next.
More news about argenx SE.
2. FedEx (FDX) – -10.97%
FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. It operates through FedEx Express, FedEx Ground, FedEx Freight, and FedEx Services segments. The FedEx Express segment offers express transportation, small-package ground delivery, and freight transportation services; and time-critical transportation services. The FedEx Ground segment provides small-package ground delivery services. The FedEx Freight segment offers less-than-truckload freight transportation services. The FedEx Services segment provides sales, marketing, information technology, communications, customer service, technical support, billing and collection, and back-office support services. In addition, the company offers supply chain management solutions; and air and ocean cargo transportation, specialty transportation, customs brokerage, and trade management tools and data. The company was founded in 1971 and is headquartered in Memphis, Tennessee.
NYSE ended the session with FedEx dropping 10.97% to $249.29 on Thursday, following the last session’s downward trend. NYSE dropped 1.34% to $16,573.78, after two consecutive sessions in a row of gains, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, FedEx has a trailing twelve months EPS of $16.38.
PE Ratio
FedEx has a trailing twelve months price to earnings ratio of 15.22. Meaning, the purchaser of the share is investing $15.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.16%.
Volume
Today’s last reported volume for FedEx is 12257100 which is 553.85% above its average volume of 1874600.
Previous days news about FedEx
- Fedex (fdx) Q2 earnings and revenues lag estimates. According to Zacks on Tuesday, 19 December, "While FedEx has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Fedex (fdx) reports Q2 earnings: what key metrics have to say. According to Zacks on Tuesday, 19 December, "For the quarter ended November 2023, FedEx (FDX Quick QuoteFDX – Free Report) reported revenue of $22.17 billion, down 2.8% over the same period last year. ", "Here is how FedEx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about FedEx.
3. MicroVision (MVIS) – -7.19%
MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.
NASDAQ ended the session with MicroVision falling 7.19% to $2.58 on Thursday while NASDAQ dropped 1.5% to $14,777.94.
Earnings Per Share
As for profitability, MicroVision has a trailing twelve months EPS of $-0.43.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -83.29%.
Yearly Top and Bottom Value
MicroVision’s stock is valued at $2.58 at 01:32 EST, way below its 52-week high of $8.20 and way higher than its 52-week low of $1.82.
Volume
Today’s last reported volume for MicroVision is 2151180 which is 4.1% above its average volume of 2066420.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroVision’s stock is considered to be overbought (>=80).
Moving Average
MicroVision’s worth is way above its 50-day moving average of $2.16 and way under its 200-day moving average of $2.89.
Previous days news about MicroVision
- Microvision (mvis) reaffirms revenue guidance for this year. According to Zacks on Monday, 18 December, "In the third quarter’s earnings call, MicroVision announced that it is optimistic about generating profits on the realization of its Request for Quotes, adding to its non-recurring engineering revenues from OEMs for customizing sensors. "
More news about MicroVision.
4. Viking Therapeutics (VKTX) – -5.69%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
NASDAQ ended the session with Viking Therapeutics sliding 5.69% to $18.06 on Thursday while NASDAQ fell 1.5% to $14,777.94.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.12%.
Volume
Today’s last reported volume for Viking Therapeutics is 984555 which is 60.41% below its average volume of 2487360.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be oversold (<=20).
More news about Viking Therapeutics.
5. Aon plc (AON) – -5.54%
Aon plc, a professional services firm, provides advice and solutions to clients focused on risk, retirement, and health worldwide. It offers commercial risk solutions, including retail brokerage, specialty solutions, global risk consulting and captives management, and affinity programs; and health solutions, such as health and benefits brokerages, and health care exchanges. The company also provides treaty and facultative reinsurance, as well as insurance-linked securities, capital raising, strategic advice, restructuring, and mergers and acquisitions services; and corporate finance advisory services. In addition, it offers strategic design consulting services on their retirement programs, actuarial services, and risk management services; advice services on developing and maintaining investment programs across a range of plan types, including defined benefit plans, defined contribution plans, endowments, and foundations for public and private companies, and other institutions; and advice and solutions that help clients in risk, health, and wealth through commercial risk, reinsurance, health, and wealth solutions. Aon plc was founded in 1919 and is headquartered in Dublin, Ireland.
NYSE ended the session with Aon plc sliding 5.54% to $295.66 on Thursday, following the last session’s downward trend. NYSE dropped 1.34% to $16,573.78, after two consecutive sessions in a row of gains, on what was an all-around down trend exchanging session today.
Earnings Per Share
As for profitability, Aon plc has a trailing twelve months EPS of $13.18.
PE Ratio
Aon plc has a trailing twelve months price to earnings ratio of 22.43. Meaning, the purchaser of the share is investing $22.43 for every dollar of annual earnings.
Moving Average
Aon plc’s worth is below its 50-day moving average of $324.28 and below its 200-day moving average of $324.16.
Volume
Today’s last reported volume for Aon plc is 1768840 which is 102.37% above its average volume of 874034.
More news about Aon plc.
6. Virgin Galactic (SPCE) – -5.3%
Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.
NYSE ended the session with Virgin Galactic sliding 5.3% to $2.50 on Thursday while NYSE slid 1.34% to $16,573.78.
Earnings Per Share
As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.81.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -90.56%.
Volume
Today’s last reported volume for Virgin Galactic is 5136960 which is 54.69% below its average volume of 11337800.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be overbought (>=80).
Sales Growth
Virgin Galactic’s sales growth is 244.1% for the current quarter and 315.5% for the next.
More news about Virgin Galactic.
7. Nio (NIO) – -5.21%
NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger and Destination Charger; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service. In addition, it provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; repair and routine maintenance; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Further, the company involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.
NYSE ended the session with Nio falling 5.21% to $8.36 on Thursday while NYSE fell 1.34% to $16,573.78.
Earnings Per Share
As for profitability, Nio has a trailing twelve months EPS of $-1.78.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.57%.
Previous days news about Nio
- According to Zacks on Tuesday, 19 December, "In an effort to boost efficiency, Nio slashed one-tenth of its workforce and deferred non-core projects.", "Widening losses and price cuts by competitors forced Nio to lower its prices for all models."
More news about Nio.
8. Duke Energy Corporation 5.125% Junior Subordinated Debentures due 2073 (DUKH) – -4.82%
NYSE ended the session with Duke Energy Corporation 5.125% Junior Subordinated Debentures due 2073 dropping 4.82% to $25.28 on Thursday while NYSE slid 1.34% to $16,573.78.
PE Ratio
Duke Energy Corporation 5.125% Junior Subordinated Debentures due 2073 has a trailing twelve months price to earnings ratio of 5.99. Meaning, the purchaser of the share is investing $5.99 for every dollar of annual earnings.
More news about Duke Energy Corporation 5.125% Junior Subordinated Debentures due 2073.
9. DexCom (DXCM) – -4.78%
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
NASDAQ ended the session with DexCom dropping 4.78% to $117.40 on Thursday while NASDAQ dropped 1.5% to $14,777.94.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.91.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 129.01. Meaning, the purchaser of the share is investing $129.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.42%.
More news about DexCom.
10. Li Auto (LI) – -4.34%
Li Auto Inc., through its subsidiaries, designs, develops, manufactures, and sells new energy vehicles in the People's Republic of China. The company provides Li ONE and Li L series smart electric vehicles. It also offers sales and after sales management, and technology development and corporate management services, as well as purchases manufacturing equipment. The company offers its products through online and offline channels. The company was formerly known as Leading Ideal Inc. and changed its name to Li Auto Inc. in July 2020. Li Auto Inc. was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
NASDAQ ended the session with Li Auto falling 4.34% to $33.74 on Thursday while NASDAQ slid 1.5% to $14,777.94.
Earnings Per Share
As for profitability, Li Auto has a trailing twelve months EPS of $0.23.
PE Ratio
Li Auto has a trailing twelve months price to earnings ratio of 146.7. Meaning, the purchaser of the share is investing $146.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.89%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Li Auto’s EBITDA is 0.36.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 800% and 241.7%, respectively.
More news about Li Auto.
Stay up to date with our winners and losers daily report
